Hypoxia Conditioning for High-Altitude Pre-acclimatization

Martin Burtscher1,2 · Grégoire P. Millet3,4 · Johannes Burtscher3,4

Received: 1 August 2021 / Accepted: 15 October 2021 / Published online: 9 January 2022 © The Author(s) 2022

Abstract

Purpose Main purposes of pre-acclimatization by hypoxia conditioning (HC) are the prevention of high-altitude illnesses and maintenance of aerobic exercise performance. However, robust evidence for those effects or evidence-based guidelines for exposure strategies, including recommendations to ensure safety, are largely lacking. Therefore, we summarize the current knowledge on the physiology of acclimatization to hypoxia and HC with the aim to derive implications for pre-acclimatization strategies before going on high-altitude treks and expeditions.

Methods Based on the literature search and personal experience, core studies and important observations have been selected in order to present a balanced view on the current knowledge of high-altitude illnesses and the acclimatization process, specifically focusing on pre-acclimatization strategies by HC.

Results and Conclusions It may be concluded that in certain cases even short periods (e.g., 7 h) of pre-acclimatization by HC are effective, but longer periods (e.g., > 60 h) are needed to elicit more robust effects. About 300 h of HC (intermittently applied) may be the optimal preparation for extreme altitude sojourns, although every additional hour spent in hypoxia may confer further benefits. The inclusion of hypobaric exposures (i.e., real altitude) in pre-acclimatization protocols could further increase their efficacy. The level of simulated altitude is progressively increased or individually adjusted ideally. HC should not be terminated earlier than 1–2 weeks before altitude sojourn. Medical monitoring of the pre-acclimatization program is strongly recommended.

Keywords Hypoxia · Normobaric · Hypobaric · Conditioning · Acclimatization · Altitude

Introduction

When going to high altitudes, proper acclimatization by slow ascent rates is a prerequisite in order to avoid high-altitude illnesses. This process can be supported by preceding hypoxia exposures at real altitude and/or in simulated altitude. We here define “modern” pre-acclimatization strategies as approaches that do not require actual high-altitude environments but rather take advantage of controlled indoor or laboratory conditions or tools to mimic aspects of such environments to prepare individuals to high altitude exposures. The scientific interest in and practical applications of these “modern” pre-acclimatization strategies are actually not that new [16, 23, 48, 95], but still give rise to controversy among the “high-altitude scientific community” [63, 112]. In contrast to traditional acclimatization concepts, including slow ascent and staging on the target mountain with or without preceding (pre)acclimatization at a different, more convenient (less hostile) high-altitude location [7, 77], pre-acclimatization methods by the use of simulated altitude exposures (hypoxia conditioning, HC) can be incorporated in daily life at home [23, 95]. For technical reasons (hypobaria), simulated altitude exposures in hypobaric chambers are almost exclusively used for scientific research [84, 97], rendering normobaric hypoxia within chambers or tents as well as with mask systems, the preferable means for easy-to-use pre-acclimatization purposes. Traditional acclimatization guidelines commonly suggest not to exceed an ascent rate of 500 m gain in altitude per day above 2500 m, including extra rest days for every additional ascent of...
1000–1500 m [7, 91]. Effective pre-acclimatization “at home” constitutes an attractive alternative to reduce onsite preparation and associated risks of exposure to mountain environments. It also can be tailored to individual responses to hypoxia and thus enables “precision pre-acclimatization”. However, robust evidence for those effects, evidence-based guidelines for exposure strategies and clear safety recommendations, are largely lacking.

Therefore, this review is intended to summarize and interpret existing study findings on the physiology of high-altitude acclimatization and HC effects due to intermittent exposures to simulated altitudes (hypobaric or normobaric hypoxia), yielding a state-of-the-knowledge review on the use of simulated altitude exposure for pre-acclimatization.

**Methods**

Based on the literature search and personal experience, core studies and important observations have been selected to present a balanced view on the current knowledge of high-altitude illnesses and the acclimatization process, specifically focusing on pre-acclimatization strategies by HC.

**Results and Discussion**

**The Physiology and Kinetics of Acclimatization to High Altitude/Hypoxia**

Acute exposure to both real altitude (hypobaric hypoxia) and simulated altitude (hypobaric and normobaric hypoxia) initiates similar physiological responses in order to counteract hypoxia and to improve oxygen delivery to tissues [71, 102, 104, 125]. The most relevant responses at a systemic level include hyperventilation, triggered by the hypoxic ventilatory response (HVR) [125], hemoconcentration due to diuresis [68], and the associated elevated heart rate (HR) and cardiac output (CO) due to sympathetic activation [5, 83]. Changes of resting and exercising HRs are more variable than those of ventilation. Generally, HRs increase during acute hypoxia exposure and then decrease during about 1 week of acclimatization close to baseline, depending on the altitude and physical activity performed during the altitude exposure [42]. Owing to the direct vasodilating effect of hypoxia, blood pressure is maintained or even reduced when acutely exposed to hypoxia/high altitude. However, an elevated sympathetic drive during the following days/weeks, causes an increase in blood pressure (during rest and exercise) associated with vasoconstriction, increased HR and CO [17]. The resting ventilation progressively increases during the first few days at high altitude, and levels off after 4–8 days until an altitude of about 4300 m [15, 101]. This result in partially restored alveolar oxygen partial pressure (P\textsubscript{A}O\textsubscript{2}) and reduced alveolar partial pressure of carbon dioxide (P\textsubscript{A}CO\textsubscript{2}) [72]. Consequently, the arterial partial pressure of oxygen (P\textsubscript{a}O\textsubscript{2}) and arterial oxygen saturation (Sa\textsubscript{O}2) improve (as compared to the initial impairment, but still remain below normoxic conditions) and the arterial partial pressure of carbon dioxide (P\textsubscript{a}CO\textsubscript{2}) decreases. The respiratory alkalosis (with hypocapnia) is at least partly compensated through the renal excretion of bicarbonate [130]. Characteristically, cerebral blood flow, which is primarily regulated by hypoxic vasodilation and hypocapnic/hypercapnic vasoconstriction/vasodilation, increases during the first 12 h of high altitude exposure and subsequently declines with acclimatization (within 3–5 days) to near baseline values [2]. The increase in the cerebral blood flow is closely matched to the reduction in arterial oxygen content (Ca\textsubscript{O}2) in order to maintain cerebral oxygen delivery during acclimatization [2]. Another hallmark of hypoxia exposure is hypoxia pulmonary vasoconstriction (HPV) and increased pulmonary arterial pressure [6]. Since the critical PO\textsubscript{2} that initiates HPV depends on the P\textsubscript{a}O\textsubscript{2} [116], some improvement may occur with acclimatization [90]. As true for most of the presented physiological responses to acute hypoxia and subsequent changes with acclimatization, this has also been highlighted for the HPV [45]. Schematic time courses of physiological responses during acclimatization to hypoxia (altitude) are depicted in Fig. 1.

A variety of physiological responses to hypoxia with different time courses occur at the cellular level, mediated primarily via reactive oxygen species (ROS) [113] and the activation of transcription factors including hypoxia-inducible factors (HIF) [109]. HIFs promote the expression of several hundreds of genes to maintain tissue oxygen supply. For instance, stabilization of the oxygen-regulated α-subunit (HIF-1α or its isoform HIF-2α) in hypoxia/at altitude effects the up-regulation of erythropoietin (EPO) and vascular endothelial growth factor (VEGF) transcription, promoting erythropoiesis and angiogenesis [58, 124]. Moreover, HIFs are also involved in the increase of glycolytic metabolism and the decrease of mitochondrial oxygen consumption in hypoxia [119]. Mitochondria consume the greatest portion of oxygen on the cellular level and are the main suppliers of cellular energy in the form of adenosine triphosphate (ATP) in many cell types. Hypoxia acutely induces the upregulation of glycolytic enzymes and glucose transporters, as well as a remodeling of the mitochondrial oxidative phosphorylation system to shift cellular energy metabolism more towards glycolysis [70]. Oxidative phosphorylation is modulated in response to hypoxia at several locations [69]. The upregulation of the inhibitor of respiratory complex I, NADH dehydrogenase [ubiquinone] 1 α subcomplex 4-like 2 [120] or the induction of hypoxia-activated microRNAs like miR-210, which inhibit the synthesis of important electron transport

[Springer]
system components [31, 32, 93] are examples of reducing oxygen consumption. Hypoxia-related changes of respiratory complex IV may serve to increase oxygen utilization efficiency. In hypoxic conditions the complex IV subunit COX4I1 has been reported to be degraded and substituted by the COX4I2 isoform which increases efficiency of electron transfer from complex IV to O₂ [47]. Similarly, the hypoxia-inducible gene domain family member 1A increases complex IV efficiency [60]. Such remodeling may be involved in long-term benefits of mitochondrial energy metabolism.

Plasma EPO concentration starts to increase during the first 2 h of hypoxia exposure and reaches a maximum within the first 2 days (48 h) but decreases subsequently, even if the hypoxic stimulus remains unchanged [123]. This time course of EPO concentration is paralleled by a decrease of the soluble form of the EPO receptor (sEPO-R, an endogenous antagonist of EPO) during the first 24 h at altitude/in hypoxia and subsequently remains at a reduced level, at least for 72 h [123]. The resulting EPO concentration is only slightly higher than sea level values, indicating that those minimally elevated EPO concentrations are sufficient to support erythropoiesis during chronic hypoxic conditions. Moreover, the hypoxia-stimulated production of red blood cells outweighs their degradation due to the long half life of red blood cells (about 3 months). Several further mechanisms contribute to the elevated erythropoiesis in chronic hypoxia, including upregulation of membrane EPO-R, antiapoptotic factors in erythroid progenitors in the bone marrow, and the reduced sEPO-R, which increases the free EPO concentration [76, 129]. A gradual increase of the hemoglobin mass (Hbmass) by 1% per 100 h spent at a sufficient level of hypoxia/altitude (> 2000 m) has been suggested, which seems to be independent of the altitude-exposure protocol (e.g., Live High Train High vs. Live High Train Low, see below) applied [53]. Finally, the erythropoietic response, e.g., to an altitude of 4550 m and associated increases in blood volume and red blood cells was demonstrated to slow down after about 3 months and to stabilize after about 8 months [94]. Finally, long-term exposure to hypoxia can induce the formation of new capillaries (angiogenesis), thereby supporting oxygen delivery to and aerobic metabolism of certain tissues, e.g., skeletal muscles [19]. HIF-dependent VEGF up-regulation plays a critical role for the increase in muscle capillarity and the generation of ROS, inflammatory cytokines and/or the change in the ratio of AMP/ATP are likely involved in this angiogenetic process as well [19]. Well-controlled animal (rats) experiments demonstrated an increase in the capillary-to-fiber (C/F) ratio only in relatively active, oxidative muscles (i.e., soleus and diaphragm) after a 3-week hypoxia exposure (12% oxygen) [36]. In a subsequent study, rats were exposed to hypoxia for 6 weeks, which resulted in angiogenesis in all studied muscles (also less active ones like the tibialis anterior) and a further increase of capillarity as compared to the 3-week hypoxia exposure [37]. The main systemic and cellular adaptations to hypoxia are summarized in Fig. 2.
High-Altitude Illnesses

Pre-acclimatization by HC is primarily intended to prevent high-altitude illnesses (HAI). Acute mountain sickness (AMS) and high-altitude cerebral edema (HACE) are cerebral forms of HAI because associated symptoms are primarily originating in the brain, e.g., headache [25]. While AMS is the most frequent HAI, usually benign and resolving after a few days at altitude, HACE develops rather rarely but represents a potentially life-threatening disease [25, 26, 91]. This is also true for high-altitude pulmonary edema, a pulmonary form of HAI, rarely developing below 3000 m but life-threatening if not treated immediately and appropriately [117].

The Lake Louise Scoring system (LLS) or the shortened (11-item) version (ESQ-C) of the 67-item Environmental Symptoms Questionnaire (ESQ-III) are frequently used diagnosis tools for AMS (M. [25, 26]). The LLS is a self-assessment questionnaire including five main symptoms (headache, nausea, dizziness, fatigue, and difficulty sleeping), each rated with a score from 0 to 3 (0 for no discomfort, 1 for mild, 2 for moderate, and 3 for severe symptoms). In the recently revised version of the LLS, “difficulty sleeping” has been eliminated as a questionnaire item [99]. AMS is defined as a score of 3 or higher, and the questions of the ESQ-C are scored on a scale of 0–5, with 0 reported as “not at all” and 5 as “extreme.” Each response score is multiplied by the factorial weight of its symptom and a score of 0.70 or greater is classified as AMS-C.

Effects of HC are usually evaluated by monitoring of individual physiological responses, AMS development, and/or changes in exercise performance. Whereas aerobic exercise capacity (maximal oxygen consumption, VO_{2\text{max}}) decreases with increasing altitude (related to the level of hypoxia) and is not impacted by acclimatization, submaximal performance can be partially restored through acclimatization [28, 51].

Traditional Acclimatization Strategies

Beside pre-acclimatization at higher altitudes in relative proximity to individual locations of residence, e.g., mountainous areas of the Alps, the Rockies, etc., a slow and graded ascent is the most common strategy used to prevent illnesses related to high altitude (hypoxia) exposure. Although this is a long known and still practiced strategy, only a few studies assessed the effects of the ascent rate on high altitude illnesses in a controlled fashion [18]. It is a common rule, not to exceed a daily ascent rate of 500 m (refers to the sleeping elevation) at altitudes above 2500 m [7, 91]. In addition, a resting day should be planned for every additional ascent of 1000–1500 m or in the case of health complaints. Recently, Richalet and colleagues provided a clinico-physiological score, derived from data of a multicenter study, for the identification of individuals susceptible to severe high altitude illness [98]. The authors defined an optimal ascent rate of 400 m per day (“400 m rule”) and proposed a rational decision tree for the use of acetazolamide for the prevention of high-altitude illness. “Staging” represents a somewhat different acclimatization method and refers to the concept of staying at moderate altitudes of about 2000–3000 m for several days, which subsequently permits a more rapid ascent [10, 14]. Both strategies, a slow ascent...
and staging, or a combination of both, have been tradition-
ally used in trekking and high-altitude mountaineering and
experiences from the field confirmed their effectiveness in
high-altitude illness risk management but also to improve
exercise performance [10, 14, 50].

Use and Effects of Intermittent Exposures
to Simulated Altitude

Simulated altitude (hypobaric or normobaric hypoxia) has
been explored in research since decades and nowadays is
used increasingly also for pre-acclimatization, therapeutic
and preventive purposes [4, 16, 55, 63, 97, 103, 118, 122].
Although the availability of hypobaric chambers is limited
because costs and maintenance requirements are high, the
use of normobaric hypoxia has become very popular owing
to low cost and easy-to-use devices, e.g., generators and
hypoxia breathing via face mask, hypoxia tents, or even
hypoxia rooms for exercise and/or sleeping. Delving deeper
into the complexity of differential hypoxia effects, in the
following section we will shortly discuss potential differ-
ences between normobaric and hypobaric hypoxia effects,
existing methods of hypoxia application, the use of intermit-
tent hypoxia in therapy and prevention, and finally its use
for pre-acclimatization before going to real high altitudes.
All types of hypoxia methods used for those purposes are
subsequently termed HC.

Potential Differences Between Normobaric
and Hypobaric Hypoxia

While the reduction in ambient PO₂ and subsequent hypox-
em ia are the strongest variable that trigger altitude-induced
physiological responses (see above), several slight differ-
ences have been observed between adaptations to normo-
baric and hypobaric hypoxia, pointing to a specific influence
of the barometric pressure. Preliminary results indicate a
specific effect of hypobaria on responses to hypoxia, includ-
ing differences in fluid balance [74]. Supporting these find-
ings, Conkin and Wessel [34] highlighted influences of
barometric pressure and criticized the “equivalent air alti-
tude model”. This model posits that altitude responses are
exclusively induced by the alveolar oxygen pressure (PAO₂)
decrease [33] and subsequently the magnitude of hypoxemia,
without any influence of the barometric pressure. More
recently, several research groups confirmed distinct effects of
normobaric and hypobaric hypoxia, possibly influencing the
effectiveness of the acclimatization. Although debated in the
scientific literature [85, 96], it seems that hypobaric hypoxia
is a more severe environmental condition than normobaric
hypoxia [86] that accordingly induces more severe acute
mountain sickness symptoms [39]. Amongst the variables
that may have a particular impact on (pre-)acclimatization
are differences in minute ventilation [104], in oxidative
stress [43], or cerebrovascular function [1]. It was suggested
that air density, hypoxic pulmonary vasoconstriction and cir-
culating microbubbles may interact explaining higher resting
ventilation in hypobaric than in normobaric hypoxia [75].
During exercise, the higher ventilatory response in hypo-
baric as compared to normobaric hypoxia is likely due to the
lower flow resistance in the airways in hypobaria [92], but
distinct breathing patterns (i.e., tidal volume and breathing
frequency) may also contribute to those differences [104].
Moreover, it was reported that sleeping in hypobaric hypoxia
leads to a larger desaturation and increased periodic breath-
ing (i.e., more hypopnea and desaturation phases) [62] than
sleeping in normobaric hypoxia. US army researchers have
performed several studies to investigate the effectiveness of
acclimatization in either normobaric and hypobaric hypoxia
prior a stay at Pikes Peak (Colorado, 4300 m) and several of
these studies were summarized in a review [48] that enabled
a robust comparison of distinct benefits and effectiveness of
hypobaric versus normobaric hypoxia pre-acclimatization
strategies. Since a larger ventilatory acclimatization and a
lesser performance decrement was observed in hypobaric
hypoxia than in normobaric hypoxia when the subjects were
transported and assessed at Pikes Peak, these authors pro-
vided clear evidence of a better effectiveness of pre-accli-
mation in hypobaric hypoxia. Moreover, the observed
partial ventilatory acclimatization to normobaric hypoxia
reported for the subjects, who were also pre-acclimatized in
normobaric hypoxia, was not as effective as pre-acclimati-
zation to hypobaric hypoxia and did not translate to lesser
AMS or performance benefits [87]. Those findings indicate
that pre-acclimatization in normobaric hypoxia could be
optimized by a combination with exposure to hypobaric
hypoxia. Indeed, this strategy—(i.e., living high—training
low and high in normobaric hypoxia followed by few days in
the Alps prior an expedition in the Himalayas) was success-
fully applied by an elite mountaineer on mount Everest [88].

Different Hypoxia Methods Used in Athletes

Historically, altitude training methods used by elite athletes
emerged in the 1960s and were limited to the “Live High-
Train High” (LHTH) method for endurance athletes aiming
to increase their oxygen transport. This “classical” method
was complemented in the 1990s by the “Live High-Train
Low” (LHTL) method, in which athletes benefit from the
higher intensity of training possible at lower elevations,
while residing at altitude [73]. In addition, innovative “Live
Low-Train High” (LLTH) methods became popular. After
2000, these three models were categorized as main altitude/ hypoxic training strategies [126, 127]. Recently, additional
hypoxic methods have emerged, such as “Repeated-Sprint
training in Hypoxia” (RSH) [54]. Nowadays, combinations
of the different methods are used to maximize the benefits, while reducing main drawbacks of the distinct strategies, for example, by combining LHTL and RSH (“Live High-Train Low and High”, LHTLH), where athletes “live high and train low except for few intense workouts in altitude” [89]. Additional benefits regarding both central aerobic fitness and peripheral muscular adaptations leading to improvement in repeated-sprint ability have been reported in team-sport players [20, 21]. The most updated panorama of all the existing hypoxic/altitude training methods can be accessed in Girard et al. [54].

Regarding the acclimatization to high altitude, for a long time only methods similar to LHTH or LHTL (i.e. long exposure to increasing altitude levels and low-intensity exercise) have been prescribed to mountaineers [97]. We [88] reported that alternative methods are also effective. To our knowledge, to date, there is no study comparing the effectiveness of “traditional” acclimatization strategies like LHTH and “recent” strategies like LHTLH.

**Intermittent Hypoxia and Hypoxia–Hyperoxia Conditioning in Therapy and the Prevention of Various Diseases**

Generally, HC is defined as an exposure to systemic and/or local hypoxia, resulting in insufficient oxygen supply to tissues, which is, in the case of systemic hypoxia, indicated by reduced SaO₂ values [55], and can be applied passively or in combination with exercise for therapeutic and/or preventive purposes. If performed intermittently, reoxygenation between hypoxic intervals may be done in normoxia (intermittent hypoxia conditioning, IHC) or in hyperoxia (intermittent hypoxia–hyperoxia conditioning, IHHC) [8, 57]. These types of HC may also be applied to some extend to induce pre-acclimatization but also to monitor individual responses to hypoxia exposure in mountaineers.

Commonly applied IHC or IHHC programs utilize repeated exposures to normobaric hypoxia (10%–16% O₂) with a duration of 3–8 min, each interspersed by exposures to normoxic (21% O₂) (IHC) or hyperoxic (30%–40% O₂) (IHHC) gas for 2–5 min, resulting in a total duration of 30–40 min per session [8, 57]. Sessions are applied at 1 or 2-day intervals over 2–8 weeks [8, 24, 27]. Gas mixtures are usually delivered via face masks, while peripheral oxygen saturation (SpO₂) and heart rate are continuously monitored by pulse-oximetry. IHC and more recently IHHC have been demonstrated to evoke beneficial health effects in patients suffering from various diseases, e.g., coronary artery disease [27], chronic obstructive pulmonary disease [24], systemic hypertension [78], metabolic disorders like diabetes [110], aging related decline in cognitive performance [107] and neurodegenerative diseases like Alzheimer’s [8, 82] or Parkinson’s disease [25, 26, 111].

HC in combination with exercise may also be performed as IHC or IHHC (previously also termed IHT or IHHT: intermittent hypoxia training and intermittent hypoxia–hyperoxia training, or using longer continuous sessions in normobaric hypoxia rooms. It has been suggested that HC with exercise might elicit synergistic effects of both stimuli, hypoxia and exercise, e.g., for the use of weight loss [65], the increase in bone density [29] and/or exercise tolerance [56, 115].

As outlined above, mechanisms responsible for hypoxia effects may be either related or unrelated to hypoxia-induced HIF activation as recently reviewed [69], and include improvements of stress resistance on the cellular and systemic level [27, 81], glucose homeostasis [41, 61] and blood lipid profile [40, 64, 110], as well as the evocation of anti-arrhythmic effects and improved autonomic cardiovascular and respiratory control [27, 59], and neuroprotection by upregulating neuroprotectants like VEGF, EPO, antioxidants and nitric oxide (NO), and/or by suppressing apoptosis [66]. Regarding IHHC, reoxygenation, especially when performed under hypoxic conditions, generates ROS, which may trigger redox-signaling cascades initiating adaptations that contribute to injury resistance, e.g., by membrane-stabilizing effects in the heart, brain, and liver [3, 105, 106, 113]. Although the multitude of signaling pathways involved in hypoxia adaptations and their interactions are far from being fully elucidated, they may not only be used for the benefit of different patient groups but also contribute to (pre-)acclimatization, improved exercise tolerance and training efficiency (demonstrated by Sazontova and colleagues [105, 106]).

**Hypoxia Conditioning for Pre-acclimatization to High Altitude**

Pre-acclimatization before high altitude sojourns for trekking or expeditions is not a novel technique. For instance, mountaineers from the Alps prepared and pre-acclimatized already in the 1950s and 60 s at altitudes (up to 4810 m) of the alpine regions before climbing in the extreme altitudes of the Himalayas. At that time, exposure to real altitude (hypobaric hypoxia) was the method of choice, but also the application of normobaric hypoxia for potential pre-acclimatization has been evaluated already more than 3 decades ago, even using a light-weight mobile device (the altitude-conditioning apparatus) [22]. In this study 12 young men were exposed to normobaric hypoxia (inspiratory oxygen concentration, FiO₂: 13.8%, about 3400 m simulated altitude) for 80 h (10 days for 8 h per day)). Subsequently, the participants were exposed to a simulated altitude of 4500 m (hypobaric chamber) for 2 days to evaluate effects of pre-acclimatization on the development of AMS. Although the authors reported no significant preventive effect, based on effect size calculations, there actually was a beneficial effect of pre-acclimatization
by repeated normobaric hypoxia exposures (AMS-C 1.60 vs. 2.61 in the experimental group vs. controls, effect size 0.7) [22]. From this study, not only optimal hypoxia levels and exposure duration, but also potential influences of normobaria vs. hypobaria remained unclear. In subsequent years/decades, numerous experiments were performed in order to clarify the effectiveness of normobaria vs. hypobaria exposure durations, differences in the use of normobaric or hypobaric hypoxia, and often considerable discrepancies of the simulated altitude of pre-acclimatization and the subsequent altitude exposure for the assessment of AMS development still do not allow a systematic evaluation of efficacy. Characteristics and effects of hypoxia conditioning studies on peripheral oxygen saturation, and/or aerobic exercise performance, and/or acute mountain sickness are summarized in Table 1. Although the findings are partly conflicting, the majority of experiments demonstrated some beneficial consequences on AMS development and/or aerobic exercise performance and importantly, no clinically relevant adverse events associated with pre-acclimatization have been reported. Various possibilities to apply normobaric hypoxia for HC and changes in the HVR and the LLS when re-exposed to simulated hypoxia (4500 m) after 7 h of HC are shown in Fig. 3.

| Reference          | No. of subjects (m/f), age, no. of controls | Altitude exposure: normobaric, hypobaric (simulated, real) | Exposure time: hours or min per day, no. of days (total hours) | Exposure type: rest/ exercise | Re-exposure: normobaric, hypobaric (simulated, real) | SpO2 (%): pre/ post vs. control (rest/exercise) | Exercise performance: post/ pre change (%) | Acute mountain sickness: LLS, pre/ post AMS incidence (%) vs. control |
|-------------------|--------------------------------------------|-----------------------------------------------------------|-------------------------------------------------------------|-------------------------------|-----------------------------------------------|-----------------------------------------------|---------------------------------------------|-----------------------------------------------|
| Beidleman et al. [11] | 5 (4/1), 23 ± 2                            | 4300 m, hypobaric (simulated)                             | 4, 15 (60)                                                  | Rest + ex                    | 4300 m, hypobaric (simulated)                 | 82/90 (rest) vs. 74/78 (ex)                  | +18 (VO2max) +21 (time trial)               | n/a                                           |
| Faulhaber et al. [46] | 33 (16/17), 38 ± 12, 6                        | 4500 m, normobaric                                         | 1, 7 (7)                                                   | Rest                          | 3650 m, hypobaric (real)                     | Baseline/3650 m vs. 97/90 (rest)            | n/a                                         | AMS incidence: 59 vs. 67 (ns)                 |
| Dehnert et al. [35] | 73 (73/0), 26.5, 38                          | 2500–3300 m, normobaric                                   | ~7, 14 (~100)                                              | Rest (sleep)                 | 4500 m, normobaric                           | vs. control 78.5/81.2 (rest)               | n/a                                         | AMS incidence: 14 vs. 52 (s)                 |
| Schommer et al. [108] | 40 (22/18), 33 ± 7, 20                        | 2500–4500 m, normobaric                                   | (70 min, 9) + (90 min, 4) (16.5)                           | Rest + ex                    | 3611 m, hypobaric (real)                     | vs. control 86.4/84.3                      | n/a                                         | AMS incidence: 6 vs. 47 (s)                 |
| Schommer et al. [108] | 40 (22/18), 33 ± 7, 20                        | 2500–4500 m, normobaric                                   | (70 min, 9) + (90 min, 4) (16.5)                           | Rest + ex                    | 4559 m, hypobaric (real)                     | vs. control 73.6/75.8                      | n/a                                         | AMS incidence: 60 vs. 70 (ns)               |
| Treml et al. [121]  | 49 (25/24), 24 ± 3, 26                        | 4500 m, normobaric                                         | 1, 7 (7)                                                   | Rest                          | 4500 m, normobaric                           | 81/85 (rest)                               | n/a                                         | LLS: 2.8 vs. 1.3 (s)                        |
| Wille et al. [128]  | 26 (26/0), 26 ± 4, 13                         | 4500 m, normobaric                                         | 1, 7 (7)                                                   | Rest                          | 4500 m, normobaric                           | HVR: +50% from baseline                    | n/a                                         | AMS incidence: 54 vs. 69 (ns)               |
We previously summarized effects of repeated normobaric or hypobaric hypoxia exposures on ventilatory acclimatization, AMS development and/or aerobic exercise performance based on the findings of 21 studies [23]. The majority of studies reported some evidence of ventilatory acclimatization and HVR increase following HC. All studies evaluating AMS development and/or psychophysical performance after HC found beneficial effects, which occurred largely independently of the activity level (rest or exercise) during hypoxia exposure [23]. Exposure durations of 1–3 h per day for at least 1 week seem to be necessary for the induction of effective pre-acclimatization. The resulting benefits are thought to be preserved for about 1 week. Mostly, the hypoxia levels used were equivalent to about 4000 m (FiO2 of about 12%). One study, in which the exposure to moderate hypoxia (FiO2: 15.5%) did not cause HVR increase, suggests attenuated or no acclimatizing effects from such mild hypoxia protocols [67]. The majority of studies have been performed under resting conditions, but those directly comparing potential differences between rest and exercise in hypoxia did not see any differences [11, 12].

HC studies performed in hypobaric hypoxia (hypobaric chamber, 4000–5500 m) demonstrated a clear erythropoietic response to 3–5 h per day of hypoxia exposure over 9 days [100]. Another similar study with a 17-day hypoxia exposure (+ light aerobic exercise) confirmed the initiation of altitude acclimatization [30]. Ricart and colleagues exposed nine participants to a simulated altitude of 5000 m (hypobaric chamber) for 2 h per day for 14 days (total of 28 h) [95] and found that during submaximal aerobic exercise in hypoxia SpO2 values rose from 65% to 71% and minute ventilation rose from 55.5 to 67.6 L/min [95]. Beidleman et al. exposed sea level residents for 4 h to hypobaric hypoxia (simulated altitude of 4300 m) for 5 days/week over 3 weeks (total 60 h). Exercise testing in hypoxia pre- and post-intervention revealed a 21% improved aerobic exercise performance (cycling time trial) post-IHT [11], and a decrease of the AMS incidence from 50% pre-HC to 0% post-HC [12].

Beneficial HC effects have also been reported for normobaric hypoxia. For instance, Schommer and colleagues exposed 40 participants to normobaric hypoxia (simulating 2500, 3000, and 3500 m during 3 weeks + exercise) [108]. The participants exercised for 70 min, three times per week at their individual 60% VO2 max and additionally were passively exposed to hypoxia four times for 90 min in week 4 (total exposure time of 16.5 h). Five days after completing the program, the participants ascended to 4559 m real altitude. While at 3611 m, the AMS incidence was only 6% in HC subjects as compared to 47% in controls, AMS was not different between the groups at 4559 m [108]. From these findings it may be concluded that acclimation effects after HC are effective up to the altitude (hypoxia level) used during HC, but may not prevent from AMS when climbing much higher. This is also true for findings from another study, where 23 subjects slept seven nights for 7.5 h (total 52.5 h) in normobaric hypoxia (FiO2 decreasing to 14.4%, 3100 m) [49]. Subsequently, the participants ascended to 4300 m real altitude for 5 days. SpO2 during sleep at altitude was significantly higher in the HC group, 80% vs. 76% in the
control group, and AMS was reduced (only) upon awakening in the HC group (AMS-C 0.34 vs. 0.83, $P < 0.02$).

A HC protocol exposing individuals to 12% $\text{FiO}_2$ for 4 h per day was suggested to promote acclimatization by attenuation of hypoxia-induced inflammation and dyslipidemia [52]. Exposure to high altitude after this type of IHT, resulted in significantly higher $\text{SpO}_2$ values and lower AMS incidence as compared to controls and was associated with lower levels of acute-phase proteins like C-reactive protein (CRP), serum amyloid A-1 protein (SAA), and fibrinogen (FGA, FGB, and FGG) [52].

We recently demonstrated that even short hypoxia bouts (1 h at $\text{FiO}_2$ of 11%) for 7 consecutive days, effectively reduced the AMS incidence during hypoxia re-exposure 7 days after completing the HC program (87% showed a lower LLS in the IH vs. 50% in the control group) [121]. Subjects susceptible to high-altitude pulmonary edema (HAPE), who often have low HVR, may benefit from such short HC [23]. HAPE represents a non-cardiogenic pulmonary edema, which is provoked by exaggerated hypoxic pulmonary vasconstriction and an increase in pulmonary artery and capillary pressure [25, 26].

Although both normobaric and hypobaric HC induce acclimatization, hypobaric HC might be somewhat more effective in the prevention of AMS, as it was shown that hypoxia, hypobaria and prolonged aerobic exercise were all independently predictive for the severity of AMS development [38]. Potential (patho-)physiological differences between normobaric and hypobaric hypoxia have recently been extensively discussed [85, 96]. The importance of exhaustive exercise on the AMS incidence was demonstrated in epidemiological studies [80].

Effects of long pre-acclimatization protocols before going to very high altitudes (> 8000 m) have very recently been reported [118]. The concept of long-duration HC (6–8 weeks) is based on successful case studies in expedition participants performed in our lab. Selected results of such a case study are depicted in Fig. 4. Participants of commercial expeditions, who rapidly (from home and back within 3 weeks) ascended Mt. Everest (8849 m), carried out 8 weeks of HC, reaching sleeping altitudes equivalent to 7100 m, and overall spent at least 300 h in hypoxia [118]. These participants tolerated the subsequent rapid ascent up to above 6000 m (without supplemental oxygen) well and successfully climbed Mt. Everest (8849 m), carried out 8 weeks of HC, reaching sleeping altitudes equivalent to 7100 m, and overall spent at least 300 h in hypoxia [118]. These participants tolerated the subsequent rapid ascent up to above 6000 m (without supplemental oxygen) well and successfully climbed Mt. Everest (8849 m), carried out 8 weeks of HC, reaching sleeping altitudes equivalent to 7100 m, and overall spent at least 300 h in hypoxia [118].

As these findings are preliminary and sometimes even controversial, largely based on uncontrolled studies and case reports, future well-controlled experiments are needed including a broad range of age categories of both sexes, using different hypoxia-exposure protocols and proper evaluation of pre-acclimation effects when subsequently exposed to real altitude.

**How Long are (Pre-)acclimatization Effects Retained?**

Finally, the question arises for how long (pre-)acclimatization effects can be retained to attenuate AMS development upon re-exposure to high altitude. This question has been addressed by Lyons and colleagues, who re-exposed 6 male lowlanders to high altitude (4300 m in a hypobaric chamber) after an 8-day stay at sea level following a 16-day acclimatization period at 4300 m at real altitude [79]. When compared with the first day at real high altitude (4300 m), mean AMS-C scores were significantly reduced from 0.6 to 0.1 during re-exposure, and only one person got sick when re-exposed as compared to four subjects at the initial exposure to real altitude. Retained acclimatization was also confirmed by elevated $\text{SpO}_2$, hemoglobin and hematocrit values during re-exposure [79]. In another study, effects of prior acclimatization (5260 m) on the cerebrovascular and ventilatory responsiveness to carbon dioxide have been assessed in 21 individuals during re-exposure after 7 and 21 days following a 7-day stay at low altitude (1500 m) [44]. These authors demonstrated that the enhanced ventilatory $\text{CO}_2$ response was partly retained only after 7 days at low altitude. The molecular basis of faster acclimatization upon re-ascent to high altitude may
include the induction of higher plasma adenosine levels during re-ascent as a consequence of erythrocyte hypoxic memory [114].

In another study, out of 17 young sea level residents, 88% developed AMS (using the LLQ criteria) during the initial high-altitude exposure (4300 m), which declined to 0% during the 12-day acclimatization period [9]. Upon re-exposure to a simulated altitude of 4300 m (hypobaric chamber) after a 12-day stay at sea level, only 17% developed AMS, indicating that a large acclimatization effect was retained. Interestingly, normobaric hypoxia exposure (3 h per day during the sea level stay) did not further reduce AMS development [9]. These findings, however, rather demonstrate a prolonged (12 days) effectiveness of prior acclimatization rather than corroborating ineffectiveness of normobaric hypoxia for pre-acclimatization.

It may be concluded that in certain cases even short periods (e.g., 7 h) of pre-acclimatization by HC are effective, but longer periods (e.g., > 60 h) are needed to elicit more robust effects. Based on case observations and time courses of various physiological responses to acute hypoxia (Fig. 1), about 300 h of HC (intermittently applied) may yield optimal acclimatization effects for extreme altitude exposures [118], but every hour spent in hypoxia may add further benefits. If possible, the inclusion of hypobaric exposures (i.e., HC) prior to high-altitude climbing may reduce AMS symptoms and enhance the chance to succeed in high-altitude expeditions [63], but robust evidence for those effects is lacking and particular attention has to be paid to safety issues.

A large heterogeneity of conditions and the (mostly) lacking evaluation of HC effects at subsequent real high-altitude exposure of available studies, currently impede a clear definition of optimal parameters for optimum pre-acclimatization. Further, great differences in individual capacities to tolerate and adapt to hypoxia highlight the need for individually tailored HC. The application of a broad range of (intermittent) HC exposure times (up to 300 h), as well as the inclusion of both sexes of various age ranges in future studies and the comparison of physiological responses during HC and associated effects during the subsequent real altitude exposure have the potential to greatly advance the field. Moreover, possible benefits of adding various periods of real (hypobaric) altitude exposures to normobaric HC need to be evaluated.

**Fig. 5** Schematic presentation of recommendations about hypoxia conditioning/pre-acclimatization in normobaric (complemented by hypobaric) hypoxia. Hypoxia severity in (simulated) altitude will progressively increase (from about 2000–5000 m) during the total exposure time (intermittent exposures during day and especially night time; with and without exercise) of about 200–300 h

HC should not be stopped earlier than 1–2 weeks before the altitude sojourn. As both the tolerance to altitude/hypoxia and the time course of acclimati(zati)on differ largely between individuals, proper medical monitoring is needed. This includes periodical recordings of SpO2, HR and blood pressure changes during day and night time, individual well-being/complaints (AMS scoring), sleep quality and quantity. Moreover, conditions in the hypoxia tent/room, i.e., PiO2, PiCO2, temperature, and humidity need to be closely monitored, triggering an alarm when certain limits are exceeded.

Comprehensive future studies evaluating individual responses to various pre-acclimatization strategies including effects of age, sex, exercise, diet, and sleep are required to increase our understanding of HC. This has also recently been pointed out by an opinion position by members of the Union Internationale des Associations d’Alpinisme Medical Commission (UIAA MedCom). The authors conclude that exposures to intermittent normobaric hypoxia (i.e., HC) prior to high-altitude climbing may reduce AMS symptoms and enhance the chance to succeed in high-altitude expeditions [63], but robust evidence for those effects is still lacking and particular attention has to be paid to safety issues.

**Conclusions**

Taken together, HC has great potential not only to conveniently be applied as a pre-acclimatization strategy before high altitude exposure but also may be highly effective as a treatment strategy for a variety of diseases apart from HAIs and to improve aerobic exercise performance. The lack of clear guidelines for HC and conclusive results demonstrating HC robustness, however, indicate that this research field is still in its infancy and will massively benefit from systematic evaluations not only of the effects of hypoxia parameters (including duration, frequency and severity) but also on the responsiveness of different target groups, including athletes and patients suffering from various diseases.
22. Burse RL, Forte VA. Acute mountain sickness at 4500 m is not altered by repeated eight-hour exposures to 3200–3550 m normobaric hypoxic equivalent. Aviat Space Environ Med. 1988;59(10):942–9.

23. Burtscher M, Brandstatter E, Gatterer H. Preacclimatization in simulated altitudes. Sleep Breath. 2008;12(2):109–14. https://doi.org/10.1007/s11325-007-0127-9.

24. Burtscher M, Haider T, Domej W, Linser T, Gatterer H, Faulhaber M, Bernardi L. Intermittent hypoxia increases exercise tolerance in patients at risk for or with mild COPD. Respir Physiol Neurobiol. 2009;165(1):97–103. https://doi.org/10.1016/j.resp.2008.10.012.

25. Burtscher M, Hefti U, Hefti JP. High-altitude illnesses: Old stories and new insights into the pathophysiology, treatment and prevention. Sports Med Health Sci. 2021b;3(2):59–69. https://doi.org/10.1016/j.smhs.2021.04.001.

26. Burtscher J, Mallet RT, Burtscher M, Millet GP. Hypoxia and brain aging: neurodegeneration or neuroprotection? Ageing Res Rev. 2021a;68:101343. https://doi.org/10.1016/j.arr.2021.101343.

27. Burtscher M, Pachinger O, Ehrenbourg I, Mitterbauer G, Faulhaber M, Pühringer R, Tkatchouk E. Intermittent hypoxia increases exercise tolerance in elderly men with and without coronary artery disease. Int J Cardiol. 2004;96(2):247–54. https://doi.org/10.1016/j.ijcard.2003.07.021.

28. Calbet JA, Boushel R, Radegran G, Sondergaard H, Wagner PD, Saltin B. Why is VO2 max after altitude acclimatization still reduced despite normalization of arterial O2 content? Am J Physiol Regul Integr Comp Physiol. 2003;284(2):R304-316. https://doi.org/10.1152/ajpregu.00156.2002.

29. Camacho-Cardenosa M, Camacho-Cardenosa A, Timón R, Olcina G, Tomas-Carús P, Brazo-Sayavera J. Can hypoxic conditioning improve bone metabolism? A systematic review. Int J Environ Res Public Health. 2019;16(10):1799. https://doi.org/10.3390/ijerph16101799.

30. Casas M, Casas H, Pagès T, Rama R, Ricart A, Ventura JL, Viscor G. Intermittent hypobaric hypoxia induces altitude acclimation and improves the lactate threshold. Aviat Space Environ Med. 2009;71(2):125–30.

31. Chan SY, Zhang Y-Y, Hemann C, Mahoney CE, Zweier JL, Loscalzo J. MicroRNA-210 controls mitochondrial function and decreases ISCU and COX10 expression. Oncogene. 2010;29(30):4362–8.

32. Chan SY, Zhang Y-Y, Hemann C, Mahoney CE, Zweier JL, Loscalzo J. MicroRNA-210 modulates mitochondrial function and decreases ISCU1/2. Cell Metab. 2009;10(4):273–84.

33. Conkin J. Equivalent air altitude and the alveolar gas equation. Aviat Space Environ Med. 2015;47(10):2140–9. https://doi.org/10.1249/MSS.0000000000000630.

34. DiPasquale DM, Strangman GE, Harris NS, Muza SR. Hypoxia, hypobaria, and exercise duration affect acute mountain sickness. Aerosp Med Hum Perform. 2015;86(7):614–9. https://doi.org/10.3357/AMHP.4266.2015.

35. DiPasquale DM, Strangman GE, Harris NS, Muza SR. Acute mountain sickness symptoms depend on normobaric versus hypobaric hypoxia. Biomed Res Int. 2016;2016:6245609. https://doi.org/10.1155/2016/6245609.

36. Du X, Giraud O, Fan RY, Ma F. Effects of active and passive hypoxic conditioning for 6 weeks at different altitudes on blood lipids, leptin, and weight in rats. High Alt Med Biol. 2020;21(3):243–8. https://doi.org/10.1089/ham.2020.0003.

37. Deveci D, Marshall JM, Egginton S. Chronic hypoxia induces prolonged angiogenesis in skeletal muscles of rat. Exp Physiol. 2002;87(3):287–91. https://doi.org/10.1113/eph8702377.

38. Deveci D, Marshall JM, Egginton S. Chronic hypoxia induces prolonged angiogenesis in skeletal muscles of rat. Exp Physiol. 2002;87(3):287–91. https://doi.org/10.1113/eph8702377.

39. Deveci D, Marshall JM, Egginton S. Chronic hypoxia induces prolonged angiogenesis in skeletal muscles of rat. Exp Physiol. 2002;87(3):287–91. https://doi.org/10.1113/eph8702377.
52. Gangwar A, Pooja, Sharma M, Singh K, Patyal A, Bhaumik G, Sethy NK. Intermittent normobaric hypoxia facilitates high altitude acclimatization by curtailting hypoxia-induced inflammation and dyslipidemia. Pflugers Arch. 2019;471(7):949–59. https://doi.org/10.1007/s00424-019-02273-4.

53. Garvican L, Martin D, Quod M, Stephens B, Sassi A, Gore C. Time course of the hemoglobin mass response to natural altitude training in elite endurance cyclists. Scand J Med Sci Sports. 2012;22(1):95–103. https://doi.org/10.1111/j.1600-0838.2010.01145.x.

54. Girard O, Brocherie F, Millet GP. Effects of altitude/hypoxia on single- and multiple-sprint performance: a comprehensive review. Sports Med. 2017;47(10):1931–49. https://doi.org/10.1007/s40279-016-0733-z.

55. Girard O, Matic Girard I, Peeling P. Hypoxic conditioning: a novel therapeutic solution for load-compromised individuals to achieve similar exercise benefits by doing less mechanical work! Br J Sports Med. 2020. https://doi.org/10.1136/bjsports-2020-103186.

56. Girard O, Willis SJ, Purnelle M, Scott BR, Millet GP. Separate and combined effects of local and systemic hypoxia in resistance exercise. Eur J Appl Physiol. 2019;119(10):2313–25. https://doi.org/10.1007/s00424-019-04217-3.

57. Glazachev O, Kopylov P, Susta D, Dudnik E, Zagaynaya E. Adaptations following an intermittent hypoxia–hyperoxia training in coronary artery disease patients: a controlled study. Clin Cardiol. 2017;40(6):370–6. https://doi.org/10.1002/clc.22670.

58. Glazachev O, Kopylov P, Susta D, Dudnik E, Zagaynaya E. Adaptations following an intermittent hypoxia–hyperoxia training in coronary artery disease patients: a controlled study. Clin Cardiol. 2017;40(6):370–6. https://doi.org/10.1002/clc.22670.

59. Haider T, Casucci G, Linser T, Faulhaber M, Gatterer H, Ott G, Heidler T. Preacclimatization for exercise. Eur J Appl Physiol. 2019;119(10):2313–25. https://doi.org/10.1007/s00424-019-02273-4.

60. Hobbins L, Hunter S, Caoneta P, Preacclimatization for exercise. Eur J Appl Physiol. 2019;119(10):2313–25. https://doi.org/10.1007/s00424-019-02273-4.

61. He S, Li J, Wang J, Zhang Y. Hypoxia exposure alleviates pulmonary edema in experimental sepsis. PLoS One. 2019;14(9):e0226793. https://doi.org/10.1371/journal.pone.0226793.

62. Heinzer R, Saugy JJ, Rupp T, Tobback N, Fais S, Bourdillon F, Heffeler J, Parsons N, Millet GP. Comparison of sleep disorders between real and simulated 3,450-m altitude. Sleep. 2016;39(8):1517–23. https://doi.org/10.1093/sleep/6010.

63. Hilty MP, Hefti U, Brugger H, Bouzat P. Preacclimatization for exercise. Eur J Appl Physiol. 2019;119(10):2313–25. https://doi.org/10.1007/s00424-019-02273-4.

64. Hilty MP, Hefti U, Brugger H, Bouzat P. Preacclimatization for exercise. Eur J Appl Physiol. 2019;119(10):2313–25. https://doi.org/10.1007/s00424-019-02273-4.

65. Hobbins L, Hunter S, Gaoua N, Girard O. Higd1a is a positive regulator of cytochrome c oxidase. Proc Natl Acad Sci. 2015;112(5):1553–8. https://doi.org/10.1097/HJH.0b013e32832c0018.

66. Hobbins L, Hunter S, Gaoua N, Girard O. Higd1a is a positive regulator of cytochrome c oxidase. Proc Natl Acad Sci. 2015;112(5):1553–8. https://doi.org/10.1097/HJH.0b013e32832c0018.

67. Katayama K, Sato K, Hotta N, Ishida K, Iwasaki K, Miyamura M. Intermittent hypoxia does not increase exercise ventilation at simulated moderate altitude. Int J Sports Med. 2007;28(6):480–7. https://doi.org/10.1055/s-2006-955895.

68. Koller EA, Bührer A, Felder L, Schopen M, Vallotton MB. Altitude diuresis: endocrine and renal responses to acute hypoxia of acclimatized and non-acclimatized subjects. Eur J Appl Physiol Occup Physiol. 1991;62(3):228–34. https://doi.org/10.1007/BF00643747.

69. Lee P, Chandel NS, Simon MC. Cellular adaptation to hypoxia through hypoxia-inducible factors and beyond. Nat Rev Mol Cell Biol. 2020;21(5):268–83. https://doi.org/10.1038/s41580-020-0227-y.

70. Lendahl U, Lee KL, Yang H, Poellinger L. Generating specificity and diversity in the transcriptional response to hypoxia. Nat Rev Genet. 2009;10(12):821–32. https://doi.org/10.1038/nrg2665.

71. Levine BD, Zuckerman JH, deFilippi CR. Effect of high-altitude exposure in the elderly: the Tenth Mountain Division Study. Circulation. 1997;96(4):1224–32.

72. Lenfant C, Sullivan K. Adaptation to high altitude. N Engl J Med. 1971;284(23):1298–309. https://doi.org/10.1056/NEJM197106102842305.

73. Levine BD, Zuckerman JH, deFilippi CR. Effect of high-altitude exposure in the elderly: the Tenth Mountain Division Study. Circulation. 1997;96(4):1224–32.

74. Loeppky JA, Icenogle MV, Maes D, Riboni K, Hinghofer-Szalay B, Roach RC. Early fluid retention and severe acute mountain sickness. J Appl Physiol (1985). 2005;98(2):591–7. https://doi.org/10.1152/japplphysiol.00527.2004.

75. Loeppky JA, Scotto P, Roach RC. Acute ventilatory response to simulated altitude, normobaric hypoxia, and hypobaria. Aviat Space Environ Med. 1996;67(11):1019–22.

76. Lopez-Laval I, Legaz-Arrese A, George K, Serveto-Galindo O, González-Rave JM, Reverter-Masia J, Minguia-Izquierdo D. Oxidative stress in ethanol-withdrawn rats. J Appl Physiol. 2008;105(2):510–7. https://doi.org/10.1152/japplphysiol.09317.2008.

77. Luks AM. Clinician’s corner: what do we know about safe ascent rates at high altitude? High Alt Med Biol. 2012;13(3):147–52. https://doi.org/10.1089/ham.2012.1055.

78. Lyamina NP, Lyamina SV, Chenkina VN, Mallet RT, Downey HF, Manukhina EB. Normobaric hypoxia conditioning reduces blood pressure and normalizes nitric oxide synthesis in patients with arterial hypertension. J Hypertens. 2011;29(11):2265–72. https://doi.org/10.1007/HJ.0b013e283458846.

79. Lyons TP, Muza SR, Rock PB, Cymerman A. The effect of altitude pre-acclimatization on acute mountain sickness during reexposure. Aviat Space Environ Med. 1995;66(10):957–62.

80. Mairer K, Wille M, Bucher T, Burtscher M. Prevalence of acute mountain sickness in the Eastern Alps. High Alt Med Biol. 2009;10(3):239–45. https://doi.org/10.1089/ham.2008.1091.

81. Mallet RT, Manukhina EB, Ruelas SS, Caffrey JL, Downey HF. Cardioprotection by intermittent hypoxia conditioning: evidence, mechanisms, and therapeutic potential. Am J Physiol Heart Circ Physiol. 2018;315(2):H216–32. https://doi.org/10.1152/ajpheart.00606.2018.

82. Manukhina EB, Downey HF, Shi X, Mallet RT. Intermittent hypoxia training protects cerebrovascular function in Alzheimer’s disease. Exp Biol Med (maywood). 2016;241(12):1351–63. https://doi.org/10.1177/1535370216649060.

83. Mazzeo RS, Bender PR, Brooks GA, Butterfield GE, Groves BM, Sutton JR, Reeves JT. Arterial catecholamine responses during exercise with acute and chronic high-altitude exposure. Am J Physiol. 1991;261(4 Pt 1):E419–424. https://doi.org/10.1152/ajpendo.1991.261.4.E419.
116. Swenson ER. Hypoxic pulmonary vasoconstriction. High Alt Med Biol. 2013;14(2):101–10. https://doi.org/10.1089/ham.2013.1010.

117. Swenson ER, Bärtsch P. High-altitude pulmonary edema. Compr Physiol. 2012;2(4):2753–73. https://doi.org/10.1002/cphy.c100029.

118. Tannheimer M, Lechner R. Rapid ascents of Mt Everest: normobaric hypoxic preacclimatization. J Travel Med. 2020. https://doi.org/10.1093/jtm/taaa099.

119. Taylor CT. Mitochondria and cellular oxygen sensing in the HIF pathway. Biochem J. 2008;409(1):19–26. https://doi.org/10.1042/BJ20071249.

120. Tello D, Balsa E, Acosta-Iborra B, Fuertes-Yebra E, Elorza A, Ordóñez Á, Perales-Clemente E. Induction of the mitochondrial NDUFA4L2 protein by HIF-1α decreases oxygen consumption by inhibiting Complex I activity. Cell Metab. 2011;14(6):768–79.

121. Treml B, Kleinsasser A, Hell T, Knotzer H, Wille M, Bartscher M. Carry-over quality of pre-acclimatization to altitude elicited by intermittent hypoxia: a participant-blinded, randomized controlled trial on antedated acclimatization to altitude. Front Physiol. 2020;11:531. https://doi.org/10.3389/fphys.2020.00531.

122. Verges S, Chacaroun S, Godin-Ribout D, Baillieul S. Hypoxic conditioning as a new therapeutic modality. Front Pediatr. 2015;3:58.

123. Vizcaino-Galindo G, León-Velarde F, Villafuerte FC. High-altitude hypoxia decreases plasma erythropoietin soluble receptor concentration in lowlanders. High Alt Med Biol. 2020;21(1):92–8. https://doi.org/10.1089/ham.2019.0118.

124. Weidemann A, Johnson RS. Biology of HIF-1alpha. Cell Death Differ. 2008;15(4):621–7. https://doi.org/10.1038/cdd.2008.12.

125. Weil JV, Byrne-Quinn E, Sodal IE, Friesen WO, Underhill B, Filley GF, Grover RF. Hypoxic ventilatory drive in normal man. J Clin Invest. 1970;49(6):1061–72. https://doi.org/10.1172/JCI106322.

126. Wilber RL. Current trends in altitude training. Sports Med. 2001;31(4):249–65.

127. Wilber RL. Application of altitude/hypoxic training by elite athletes. Med Sci Sports Exerc. 2007;39(9):1610–24. https://doi.org/10.1249/mss.0b013e3180de49e6.

128. Wille M, Gatterer H, Mairer K, Philippe M, Schwarzenbacher H, Faulhaber M, Bartscher M. Short-term intermittent hypoxia reduces the severity of acute mountain sickness. Scand J Med Sci Sports. 2012;22(5):e79-85. https://doi.org/10.1111/j.1600-0838.2012.01499.x.

129. Zon LI, Youssoufian H, Mather C, Lodish HF, Orkin SH. Activation of the erythropoietin receptor promoter by transcription factor GATA-1. Proc Natl Acad Sci USA. 1991;88(23):10638–41. https://doi.org/10.1073/pnas.88.23.10638.

130. Zouboules SM, Lafave HC, O’Halloran KD, Brutsaert TD, Nysten HE, Nysten CE, Day TA. Renal reactivity: acid–base compensation during incremental ascent to high altitude. J Physiol. 2018;596(24):6191–203. https://doi.org/10.1113/JP276973.